You are attested as a Financial Advisor / Intermediary, but this page is intended for a Institutional Investor.
You are attested as a Borrower, but this page is intended for an Institutional Investor.
You are attested as an Individual Investor, but this page is intended for an Institutional Investor.
FIXED ON ESG | EPISODE 42
Antimicrobial Resistance (AMR) is one of the most urgent health challenges today, making infections harder—and sometimes impossible—to treat. This episode of Fixed on ESG explores what AMR is, why it matters, and its wide-ranging impact on health systems and the global economy.
We also highlight the science behind resistance, why innovation in diagnostics, vaccines, and stewardship is critical, and what investors should consider as AMR drives rising healthcare costs, regulatory pressures, and opportunities in new technologies.
PGIM’s Birgit Lundem Jakobsen, ESG Specialist, hosts this discussion with Amish Acharya, Senior Scientific and Clinical Advisor from the Fleming Initiative.
Recorded on January 20, 2026.
